In addition to examining DDA effects on breast tumors with overexpression of wild type EGFR or HER2, in future studies it will be important to determine whether mutants or splice variants of these proteins, such as HER2-delta 16 [62–64] are responsive to DDAs. Here, ERBB2 is linked to breast neoplasm.